ASHBURN, Va., Aug. 8 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of three ongoing phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain.
Innocoll's BUPIVACAINE SURGICAL IMPLANT is a biodegradable and fully bioresorbable matrix of purified fibrillar collagen impregnated with the local anesthetic, bupivacaine, which has been specifically developed and formulated using Innocoll's proprietary CollaRx sponge technology. It is under development in the US and Europe for the management of post-operative pain following moderate/major abdominal, gynecological, abdominal, thoracic, and orthopedic surgeries.
Post-operative pain is typically controlled with narcotic analgesics such as morphine, but systemic administration of these drugs can result in unfavorable side effects including suppression of breathing, sedation, nausea and vomiting, and can also affect patient recovery. Innocoll's BUPIVACAINE SURGICAL IMPLANT is intended to provide pain control directly at the surgical site and thus reduce the level of additional analgesia required following surgery. The collagen matrix naturally biodegrades over a few days and the bupivacaine is released to provide local analgesia for up to 96 hours post-operatively. A key feature of Innocoll's product is the ability to implant it directly into the surgical cavity and at different layers within the wound, such as across the peritoneal incision and directly below the skin incision, which enables localized treatment of both the incisional and deep, visceral pain components normally associated with moderate and major surgery. The bioresorbable nature of the collagen matrix also offers significant clinical benefits and convenience advantages over ambulatory infusion pumps which can be used to provide continuous, long-term analgesia at the site of a surgical wound.
Innocoll has already completed a phase 2 clinical trial in patients undergoing hysterectomy surgery in the absence of gynecological cancers at Wexham Park Hospital, Slough, UK. The results of this trial were particularly encouraging, showing evidence of sustained, post-operative analgesia for approximately 96 hours as measured by VAS (visual analogue scale) scores and reduced dependence on systemic morphine administered by PCA (patient-controlled analgesia). This extended analgesic action was achieved despite a low total bupivacaine dose (150mg as the hydrochloride salt), which is well below the allowable daily dose and equivalent to that used by some practitioners for a once-off wound infiltration with bupivacaine solution prior to wound closure.
Innocoll has appointed Premier Research Group, a leading clinical research organization in acute and chronic pain, to co-ordinate a series of US phase 2 multi-centered, controlled clinical trials in a variety of surgical procedures; including hysterectomy, herniorrhaphy, and open gastrointestinal surgery. In addition to those surgeries currently being studied, other procedures where the product could potentially be used routinely include caesarean section, mastectomy, cholecystectomy, open heart surgery, vascular surgery, and various orthopedic surgeries such as hip and knee replacement, bunionectomy, open fracture repair and certain bone graft procedures.
This trial, the first of three ongoing multi-centered trials to complete patient enrollment, is a 3-way study comparing the analgesic effect of BUPIVACAINE SURGICAL IMPLANT versus placebo and standard of care in patients undergoing total abdominal hysterectomy.
Dr. Michael Myers, Innocoll's President and CEO commented "We are delighted to have enrolled the last patient in this phase 2 trial and we are now eagerly anticipating the full and final results in approximately 3 months. In the meantime, we are working diligently through our other ongoing and planned phase 2 and phase 3 clinical trials to support the development of our three leading product opportunities in post-operative pain, prevention of surgical site infection, and treatment of diabetic foot infection."
About Innocoll, Inc.
Innocoll is a privately-held biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), and CRONOCOL(R). In 2005, Innocoll acquired the worldwide marketing rights for this product from Essex Chemis AG, an affiliated company of Schering-Plough Corporation and in August 2007 sold its marketing rights with the exception of the US, to EUSA Pharma. Gentamicin Surgical Implant is currently in phase 3 development in the US for the prevention of surgical site infections. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase 2 development. For more information, please visit www.innocollinc.com.
CONTACT: Veronica Kelly, 00353 9064 86834, for Innocoll, Inc.
Web site: http://www.innocollinc.com/
